Esperion Therapeutics’ (ESPR) Buy Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Esperion Therapeutics (NASDAQ:ESPR) in a research report report published on Wednesday morning, Benzinga reports. HC Wainwright currently has a $16.00 price objective on the biopharmaceutical company’s stock.

A number of other analysts have also recently weighed in on ESPR. Needham & Company LLC decreased their price target on shares of Esperion Therapeutics from $8.00 to $6.00 and set a buy rating for the company in a research report on Tuesday, August 13th. Bank of America downgraded Esperion Therapeutics from a neutral rating to an underperform rating and dropped their target price for the company from $2.90 to $2.50 in a report on Thursday, June 20th. Finally, StockNews.com cut Esperion Therapeutics from a buy rating to a hold rating in a report on Friday, September 27th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company. According to data from MarketBeat.com, Esperion Therapeutics has an average rating of Hold and an average target price of $8.17.

Esperion Therapeutics Price Performance

Shares of NASDAQ:ESPR opened at $2.16 on Wednesday. The business has a 50-day moving average of $1.84 and a two-hundred day moving average of $2.20. The firm has a market capitalization of $409.23 million, a PE ratio of -2.18 and a beta of 1.00. Esperion Therapeutics has a 12 month low of $0.70 and a 12 month high of $3.40.

Esperion Therapeutics (NASDAQ:ESPR) last posted its earnings results on Monday, August 12th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.10. The business had revenue of $73.83 million for the quarter, compared to analyst estimates of $51.90 million. As a group, research analysts anticipate that Esperion Therapeutics will post -0.04 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the business. Bellevue Group AG increased its holdings in Esperion Therapeutics by 136.5% during the 1st quarter. Bellevue Group AG now owns 9,944,064 shares of the biopharmaceutical company’s stock worth $26,650,000 after purchasing an additional 5,739,800 shares during the last quarter. Wasatch Advisors LP grew its position in shares of Esperion Therapeutics by 2.7% during the first quarter. Wasatch Advisors LP now owns 9,129,647 shares of the biopharmaceutical company’s stock worth $24,467,000 after buying an additional 238,544 shares in the last quarter. Vanguard Group Inc. increased its stake in shares of Esperion Therapeutics by 71.8% in the first quarter. Vanguard Group Inc. now owns 8,826,546 shares of the biopharmaceutical company’s stock worth $23,655,000 after buying an additional 3,688,796 shares during the last quarter. Marshall Wace LLP increased its stake in shares of Esperion Therapeutics by 94.2% in the second quarter. Marshall Wace LLP now owns 4,303,596 shares of the biopharmaceutical company’s stock worth $9,554,000 after buying an additional 2,087,635 shares during the last quarter. Finally, GSA Capital Partners LLP raised its holdings in Esperion Therapeutics by 1.0% in the fourth quarter. GSA Capital Partners LLP now owns 1,128,149 shares of the biopharmaceutical company’s stock valued at $3,373,000 after acquiring an additional 11,494 shares in the last quarter. Institutional investors and hedge funds own 47.39% of the company’s stock.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.